BLFS - BioLife Solutions, Inc.
| Previous Close | 16.56 |
| Open | 16.52 |
| Bid | 16.20 x 800 |
| Ask | 16.24 x 800 |
| Day's Range | 16.07 - 16.62 |
| 52 Week Range | 9.15 - 26.35 |
| Volume | 70,696 |
| Avg. Volume | 146,368 |
| Market Cap | 305.866M |
| Beta (3Y Monthly) | 2.11 |
| PE Ratio (TTM) | 107.75 |
| EPS (TTM) | 0.15 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.25 |
- Insider Monkey•14 hours ago
Hedge Funds Have Never Been This Bullish On BioLife Solutions, Inc. (BLFS)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]
- PR Newswire•14 days ago
BioLife Solutions to Join Russell 3000® Index
BOTHELL, Wash., June 10, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for cell and gene therapies, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
- PR Newswire•25 days ago
BioLife Solutions to Present at the Jefferies 2019 Healthcare Conference
BOTHELL, Wash. , May 30, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary ...
- PR Newswire•26 days ago
BioLife Solutions Announces SAVSU Technologies Selected by Novartis to Supply Advanced Cold Chain Management Platform for Newly Approved Gene Therapy
Cloud-Connected, Smart Shippers and evo.is Real-Time Visibility Platform Improve Quality of Transportation and Delivery of Lifesaving Therapies BOTHELL, Wash. , May 29, 2019 /PRNewswire/ -- BioLife Solutions, ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of BLFS earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Biolife Solutions Inc Earnings Call
Motley Fool•last monthBiolife Solutions Inc (BLFS) Q1 2019 Earnings Call Transcript
BLFS earnings call for the period ending March 31, 2019.
- PR Newswire•2 months ago
BioLife Solutions Announces First Quarter 2019 Financial Results
- Revenue Increased 51% to a Record $5.8 million - Gross Margin Expanded to a Record 71.5% - Gained 19 New Direct Cell & Gene Therapy Customers - Conference Call and Webcast Begin at 4:30 pm Eastern Time ...
- Zacks•2 months ago
BioLife Solutions (BLFS) to Report Q1 Results: Wall Street Expects Earnings Growth
BioLife (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•2 months ago
BioLife Solutions to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
BOTHELL, Wash. , May 2, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and ...
- PR Newswire•3 months ago
BioLife Solutions Completes Acquisition of Astero Bio
BOTHELL, Wash., April 2, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife") today announced that it has closed the previously announced transaction for the acquisition of Astero Bio Corporation ("Astero"), an innovator in the design, development and commercialization of novel automated thawing devices for cell and gene therapies, for an upfront cash payment of $8 million. The acquisition is expected to further strengthen BioLife's position as a leading supplier of disruptive, enabling tools used in the manufacture, storage and distribution of cell and gene therapies.
- Simply Wall St.•3 months ago
Can BioLife Solutions, Inc. (NASDAQ:BLFS) Improve Its Returns?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! While some investors are already well versed in financial metricsRead More...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BLFS earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 Biolife Solutions Inc Earnings Call
- GuruFocus.com•3 months ago
BioLife Solutions Inc (BLFS) Files 10-K for the Fiscal Year Ended on December 31, 2018
BioLife Solutions Inc manufactures proprietary and generic cGMP biopreservation media products, generic formulations of blood stem cell freezing media products, custom product formulation packaging services and contract aseptic manufacturing formulation. BioLife Solutions Inc had annual average EBITDA growth of 7.40% over the past ten years. Warning! GuruFocus has detected 2 Warning Signs with BLFS.
Motley Fool•3 months agoBiolife Solutions Inc (BLFS) Q4 2018 Earnings Conference Call Transcript
BLFS earnings call for the period ending December 31, 2018.
- PR Newswire•3 months ago
BioLife Solutions Announces Fourth Quarter and Full Year 2018 Financial Results
Revenue Increased 79% for the Year to $19.7 Million Net Income of $2.9 Million Gained 84 New Direct Cell & Gene Therapy Customers Conference Call and Webcast Begin at 4:30 p.m. Eastern Time Today BOTHELL, ...
- PR Newswire•3 months ago
BioLife Solutions Expands Cell and Gene Therapy Tools Portfolio with Acquisition of Astero Bio
Gains products that automate the thawing process for high-value biologic therapies Provides access to addressable market projected to exceed $150 million by 2024 Conference call and webcast begin at 4:30 ...
- PR Newswire•4 months ago
BioLife Solutions to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on March 14, 2019
BOTHELL, Wash. , March 4, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and ...
- PR Newswire•4 months ago
BioLife Solutions to Attend and Present at Upcoming Investor and Scientific Conferences
BOTHELL, Wash. , Feb. 19, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products ...
- Zacks•4 months ago
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
- Zacks•5 months ago
Medical Products Industry Outlook: Plenty of Upside Left
Medical Products Industry Outlook: Plenty of Upside Left
- PR Newswire•5 months ago
SAVSU Technologies Launches Two New evo® Smart Shipper Models to Improve Apheresis Collection Shipments and Cryopreserved Cell and Gene Therapies
evo ACS™ Extends Thermal Protection During Shipment of Patients' T Cells for Downstream Manufacturing of CAR T-Cell Therapies DV7™ Liquid Nitrogen Dewar Offers 7 Days Frozen Storage in a Compact, Non-palletized ...
- PR Newswire•5 months ago
New Policies to Advance Development of Cell and Gene Therapies Announced by FDA
BOTHELL, Wash., Jan. 22, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new policies to advance the development of safe and effective cell and gene therapies as set forth in a statement issued by the U.S. Food and Drug Administration (FDA) on January 15, 2019.
- Zacks•5 months ago
Medical Products Industry Gathering Steam: 3 Stocks to Buy
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
- GlobeNewswire•6 months ago
Consolidated Research: 2018 Summary Expectations for Enbridge Energy Partners, Sprouts Farmers Market, BioLife Solutions, PagSeguro Digital, NutriSystem, and Employers — Fundamental Analysis, Key Performance Indications
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of BLFS earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Biolife Solutions Inc Earnings Call
